An observational study in Acute Myocardial Infarction, Ischemic Cardiomyopathy and Dilated Cardiomyopathy, sponsored by Johann Wolfgang Goethe University Hospital. Status unknown at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-26.
Sponsored by Johann Wolfgang Goethe University Hospital · Observational
This study will provide follow-up information and care of patients who have undergone autologous intracoronary bone marrow cell administration at our institution. Patients are monitored for their response to treatment, progression of heart failure and coronary artery disease, and potential later occurring effects of the administered bone marrow cells.
Patients are eligible for this follow-up study if they have received their first intracoronary bone marrow cell administration for the treatment of cardiac disease at our institution from 2001 ongoing.
Participants are generally seen in the clinic at 12 months and 5 years after cell administration, in the meantime regular yearly telephone contacts are performed until 10 years after cell transplantation.
The detailed description contains the planned procedures that are performed during the clinical visits and, if necessary, at additional contacts.
In detail, the following procedures are performed during the clinical visits and, if necessary, at additional contacts:
258 studies on the registry are indexed under Cardiomyopathy, Dilated; 65 are open to participants now.
This study's planned enrollment of 1,500 is above the median of 224 across 99 observational studies indexed under Cardiomyopathy, Dilated.
Browse Cardiomyopathy, Dilated studies →Johann Wolfgang Goethe University Hospital is the lead sponsor of 160 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients suffering from heart disease with consecutive signs of heart failure, treated in our clinic or being referred for cell therapy
Inclusion Criteria: Clinical diagnosis of heart disease with signs and symptoms of heart failure due to
Exclusion Criteria:
Patients with acute myocardial infarction treated with intracoronary administration of bone marrow derived cells
Biological: autologous bone marrow-derived cells
Patients with ischemic cardiomyopathy treated with intracoronary administration of bone marrow derived cells
Biological: autologous bone marrow-derived cells
Patients with dilated cardiomyopathy treated with intracoronary administration of bone marrow derived cells
Biological: autologous bone marrow-derived cells
autologous bone marrow-derived cells isolated by density gradient centrifugation from 50 ml bone marrow aspirate obtained under local anesthesia
Evaluation of procedural and long-term safety of intracoronary administration of bone marrow cells for the treatment for cardiac disease
Time frame: 10 years
The record gives a start of Oct 2001, a primary completion of Dec 2020 and a completion of Dec 2021. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Johann Wolfgang Goethe University Hospital →